PaweÅ, Robak

List of Publications by Year
in descending order

61 papers	1,636 citations	361413 20 h-index	302126 39 g-index
61 all docs	61 docs citations	61 times ranked	2473 citing authors

#	Article	IF	Citations
1	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomideâ€pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European Journal of Haematology, 2022, 108, 73-83.	2.2	8
2	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematology,the, 2022, 9, e98-e110.	4.6	32
3	Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. Journal of Clinical Medicine, 2022, 11, 112.	2.4	3
4	ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8001-8001.	1.6	2
5	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica, 2021, 106, 601-604.	3.5	2
6	Multifocal osteolytic lesions in hairy cell leukemiaâ€"the importance of PET/CT in diagnosis and assessment. Annals of Hematology, 2021, 100, 1641-1645.	1.8	2
7	The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers, 2021, 13, 951.	3.7	9
8	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. Polish Archives of Internal Medicine, 2021, 131, 527-534.	0.4	4
9	MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance. Current Medicinal Chemistry, 2021, 28, 6753-6772.	2.4	5
10	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Journal of Clinical Medicine, 2021, 10, 5028.	2.4	1
11	The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 12070.	4.1	3
12	Bone lesions in hairy cell leukemia: Diagnosis and treatment. European Journal of Haematology, 2020, 105, 682-691.	2.2	12
13	The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. Cancers, 2020, 12, 2569.	3.7	21
14	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	13.7	188
15	OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future Oncology, 2020, 16, 631-641.	2.4	28
16	Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	18
17	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	4.1	11
18	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	1.3	3

#	Article	IF	Citations
19	Multiple myeloma in patients up to 30Âyears of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma, 2019, 60, 471-476.	1.3	13
20	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Advances in Medical Sciences, 2019, 64, 349-355.	2.1	16
21	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	10.7	254
22	Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs in R and D, 2019, 19, 73-92.	2.2	98
23	Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Leukemia and Lymphoma, 2019, 60, 2622-2634.	1.3	13
24	Dose and drug changes in chronic lymphocytic leukemia cell response inï¿½vitro: A comparison of standard therapy regimens with two novel cyclinâ€dependent kinase inhibitors. Molecular Medicine Reports, 2019, 19, 3593-3603.	2.4	2
25	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. British Journal of Haematology, 2018, 180, 831-839.	2.5	41
26	Drug resistance in multiple myeloma. Cancer Treatment Reviews, 2018, 70, 199-208.	7.7	200
27	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452.	1.4	3
28	Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development. Oncology Letters, 2017, 13, 2079-2084.	1.8	5
29	Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, 2017, 26, 1249-1265.	4.1	31
30	Emerging antibody-drug conjugates for treating lymphoid malignancies. Expert Opinion on Emerging Drugs, 2017, 22, 259-273.	2.4	20
31	Characteristics and outcomes of patients with multiple myeloma aged 21â€“40Âyears versus 41â€“60Âyears: a multiâ€institutional caseâ€control study. British Journal of Haematology, 2016, 175, 884-891.	2.5	21
32	Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology, 2016, 43, 280-290.	2.2	25
33	Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates. BioDrugs, 2016, 30, 87-93.	4.6	7
34	Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica, 2015, 100, e207-e210.	3.5	31
35	Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic AgentsIn Vitro. Journal of Chemistry, 2015, 2015, 1-11.	1.9	0
36	Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia. International Journal of Oncology, 2015, 46, 1259-1267.	3.3	6

#	ARTICLE	IF	CITATIONS
37	Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs, 2015, 20, 423-447.	2.4	9
38	Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opinion on Investigational Drugs, 2015, 24, 1419-1431.	4.1	10
39	Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 89-128.	0.1	0
40	Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. European Journal of Cancer, 2014, 50, 2677-2684.	2.8	10
41	Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2014, 14, 651-661.	3.1	27
42	New Therapies for Chronic Lymphocytic Leukemia. Current Cancer Therapy Reviews, 2014, 9, 245-257.	0.3	0
43	BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. International Reviews of Immunology, 2013, 32, 358-376.	3.3	42
44	Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treatment Reviews, 2013, 39, 851-861.	7.7	78
45	Toward personalized therapy for chronic lymphocytic leukemia. Cancer Biology and Therapy, 2013, 14, 6-12.	3.4	6
46	A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia. Current Medicinal Chemistry, 2012, 19, 5294-5318.	2.4	22
47	Purine Nucleoside Analogs in the Treatment of Rarer Chronic Lymphoid Leukemias. Current Pharmaceutical Design, 2012, 18, 3373-3388.	1.9	33
48	Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment. Medical Oncology, 2012, 29, 2111-2126.	2.5	4
49	Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2010, 10, 1529-1543.	2.4	19
50	Usefulness of Differential Scanning Calorimetry for Monitoring Ex Vivo the Changes In Responses of CLL Cells to Anti-Cancer Drugs: Development of Personalized Therapy. Blood, 2010, 116, 4635-4635.	1.4	0
51	Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. Drugs, 2009, 69, 2415-2449.	10.9	39
52	Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. Molecules, 2009, 14, 1183-1226.	3.8	66
53	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Current Opinion in Investigational Drugs, 2009, 10, 1383-90.	2.3	35
54	The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leukemia and Lymphoma, 2008, 49, 1452-1462.	1.3	29

#	ARTICLE	IF	CITATIONS
55	New Therapies for Patients with Chronic Lymphocytic Leukemia. Current Cancer Therapy Reviews, 2008, 4, 235-242.	0.3	0
56	Current treatment options in prolymphocytic leukemia. Medical Science Monitor, 2007, 13, RA69-80.	1.1	24
57	High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement. Leukemia and Lymphoma, 2006, 47, 1667-1669.	1.3	14
58	Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leukemia and Lymphoma, 2006, 47, 2625-2634.	1.3	13
59	Cytotoxic Effect of R-Etodolac (SDX-101) in Combination with Purine Analogues or Monoclonal Antibodies on Ex-Vivo B-Cell Chronic Lymphocytic Leukemia Cells.. Blood, 2005, 106, 2122-2122.	1.4	0
60	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. Leukemia and Lymphoma, 2004, 45, 1261-1267.	1.3	13
61	Treatment Options for Autoimmune Cytopenias. Transfusion Medicine and Hemotherapy, 2004, 31, 332-340.	1.6	5